Fabomotizole

Summary

Fabomotizole (CHEMBL3707307) is a phase-3 clinical-stage small molecule (ATC N05BX04); indicated across 1 condition including anxiety.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• ATC class: N05BX04
• Indications: 1 condition
• Clinical trials: 2
• Chemistry: 307.4 Da · C15H21N3O2S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3707307
Name	Fabomotizole
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	9862937
ATC	N05BX04
Molecular formula	C15H21N3O2S
Molecular weight	307.4
InChIKey	WWNUCVSRRUDYPP-UHFFFAOYSA-N

SMILES: CCOC1=CC2=C(C=C1)N=C(N2)SCCN3CCOCC3

IUPAC name: 4-[2-[(6-ethoxy-1H-benzimidazol-2-yl)sulfanyl]ethyl]morpholine

Also known as: Afobazol, Afobazole, Aphobazole, CM-346, Fabomotizol, Fabomotizole, Obenoxazine, FABOMOTIZOLE, FABOMOTIZOLE (HYDROCHLORIDE), Fabomotizole (hydrochloride)

Patent coverage: 101 distinct patent families (199 SureChEMBL compound mentions), from 3 matched compound structure(s). One matched structure accounts for 188 (94%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 disease in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
anxiety	3	MONDO:0011918	EFO:0005230

Clinical trials

Total trials: 2.

Phase distribution

Phase	Trials
PHASE4	1
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06843044	PHASE4	RECRUITING	Efficacy and Safety of Ranquilon in Patients With Anxiety Disorders Due to Neurasthenia and Adjustment Disorders
NCT04598867	PHASE3	UNKNOWN	A Study to Assess the Efficacy and Safety of CD-008-0045 in Patients With Generalized Anxiety Disorder

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).